` 0HS8 (Caladrius Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

C
0HS8
vs
S&P 500

Over the past 12 months, 0HS8 has underperformed S&P 500, delivering a return of -24% compared to the S&P 500's +13% growth.

Stocks Performance
0HS8 vs S&P 500

Loading
0HS8
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
0HS8 vs S&P 500

Performance Gap Between 0HS8 and GSPC
HIDDEN
Show

Performance By Year
0HS8 vs S&P 500

Loading
0HS8
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Caladrius Biosciences Inc vs Peers

S&P 500
0HS8
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Caladrius Biosciences Inc
Glance View

Market Cap
37.9m USD
Industry
Biotechnology

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

0HS8 Intrinsic Value
HIDDEN
Show
Back to Top